As a result, the first-generation FLT3 tyrosine kinase inhibitor (FLT3 TKI), midostaurin, in combination with chemotherapy, was approved in 2017 for newly diagnosed FLT3-mutated AML in Europe and the United States [5,6]. The gene discussed is FLT3; the disease is acute myeloid leukemia.